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Abstract: α-Synuclein amyloid aggregation is a defining molecular feature of Parkinson’s disease,
Lewy body dementia, and multiple system atrophy, but can also be found in other neurodegenerative
disorders such as Alzheimer’s disease. The process ofα-synuclein aggregation can be initiated through
alternative nucleation mechanisms and dominated by different secondary processes giving rise to
multiple amyloid polymorphs and intermediate species. Some aggregated species have more inherent
abilities to induce cellular stress and toxicity, while others seem to be more potent in propagating
neurodegeneration. The preference for particular types of polymorphs depends on the solution
conditions and the cellular microenvironment that the protein encounters, which is likely related to the
distinct cellular locations of α-synuclein inclusions in different synucleinopathies, and the existence
of disease-specific amyloid polymorphs. In this review, we discuss our current understanding on the
nature and structure of the various types of α-synuclein aggregated species and their possible roles
in pathology. Precisely defining these distinct α-synuclein species will contribute to understanding
the molecular origins of these disorders, developing accurate diagnoses, and designing effective
therapeutic interventions for these highly debilitating neurodegenerative diseases.
Keywords: α-synuclein; amyloid aggregation; oligomer; fibril; polymorph; neurodegenerative
disorders; synucleinopathies
1. Introduction
Many neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and prion
disease, are characterized by protein inclusions that are formed by the conformational conversion of
normally soluble proteins or peptides into oligomeric intermediates and eventually amyloid aggregates
and fibrils by a process referred to as amyloid aggregation [1,2] (Figure 1). Amyloid aggregates,
typically with a fibrillar morphology, are protein self-assembled structures composed primarily of one
type of protein or peptide, which adopt a characteristic structural architecture, termed the cross-β
structure [3–8]. This particular structure consists of arrays of extended β-sheets that run the length
of the fiber, in which individual β-strands are arranged in an orientation perpendicular to the fibril
axis [3,4,7]. The molecular mechanisms by which proteins adopt this structure is of unquestionable
interest, and much progress has been recently made through the development of new experimental
approaches, and by combining experimental and theoretical methods using the formalism of chemical
kinetics [9–12]. However, there are still important questions that remain to be clarified such as how
and why a specific protein starts to self-assemble, how the acquisition of the amyloid structure occurs,
and how this process induces toxicity.
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Figure 1. Schematic representation of the process of amyloid formation according to a
nucleation-conversion-polymerization model. This model has been proposed for the process of
αS aggregation when triggered at conditions of heterogeneous primary nucleation [10]: the initially
formed oligomers slowly convert into partially formed β-sheet oligomers that further elongate and
generate fully-formed mature fibrils. Note that this is a very simplified linear representation of the real
funnel-like conformational landscape of the process.
The pathogenicity of amyloid formation has been associated with both a loss of function of the
proteins that aggregate, and a gain of toxic function through the generation and accumulation of
aggregated forms of the protein [2,13], which spread within cells and propagate toxicity from cell to
cell [14,15]. Preventing the progression and the toxicity associated with amyloid formation, however,
requires precise definitions of the protein species that are toxic, and those that are able to spread
and recruit more protein units into toxic amyloid aggregates. There is continuous discussion as to
which protein aggregated species are more damaging to cells, either the fibrillar-end products of the
aggregation reaction or the soluble oligomeric intermediate species [10,13,16–21]. Both oligomeric and
fibrillar species of multiple proteins and peptides can induce toxicity by similar mechanisms including
membrane perturbation, calcium and metal ion imbalance, oxidative stress, and overload of chaperone
and ubiquitin proteasome systems [22–29], which suggests generic aggregation and toxicity pathways
between different amyloidogenic proteins and peptides [1,13], as well as possible common mechanisms
of toxicity between oligomeric and fibrillar species.
The understanding of the role of the various aggregated species on neurodegeneration has
increased even more in complexity with recent studies showing that oligomeric species can be
generated via fibril disaggregation processes [10,30,31] and by secondary nucleation mechanisms
where the fibrillar surface can catalyze the formation of oligomeric species [32,33]. These results
suggest that the fibrillar species and amyloid inclusions can act as a source of soluble oligomeric
species, which in turn can generate new fibrillar species. At the same time, variations in the solution
conditions or the particular cellular context that the protein encounters leads to structurally different
amyloid conformations, also referred to as polymorphs, which have been associated with specific types
of pathologies [18,34,35].
In this review, we will focus on the current knowledge of the multitude of α-synuclein (αS)
aggregated species generated through amyloid self-assembled processes and the possible roles these
species could have in the development and spreading of neurodegeneration, and in the induction of
distinctive types of synucleinopathies.
2. α-Synuclein Aggregation and Synucleinopathies
αS is an intrinsically disordered protein of 140 amino acids, widely expressed throughout the
body, particularly in the central nervous system, including the dopaminergic neurons of the substantia
nigra pars compacta (SNc), excitatory neurons in the cortex, amygdala and olfactory bulb and
Int. J. Mol. Sci. 2020, 21, 8043 3 of 27
inhibitory neurons in the globus pallidus, subthalamic nucleus and substantia nigra pars reticulata [36].
Its primary sequence can be divided into three regions. The N-terminal domain (residues 1–60),
which has a predisposition to fold into amphipathic α-helices, particularly upon interaction with lipid
membranes [37,38]. The central hydrophobic region (residues 61–95), named nonamyloid β component
(NAC) region (due to historical reasons to differentiate this amyloid-prone region inαS from the amyloid
β peptide involved in Alzheimer′s disease [39,40]), which has a predisposition to fold into either α-helix
conformation upon interaction with highly negatively charged lipid membranes [41,42], or β-sheet
structure upon self-assembly [43]. And the proline-rich and highly negatively charged (at neutral
pH) C-terminal region (residues 96–140), with no structure-forming propensity. There has been some
controversy as to what would be the native conformation of the protein at physiological conditions [44].
The most accepted current paradigm is that the protein remains unfolded (as an intrinsically disordered
protein, IDP) [45,46] in the cytosol, although with some tertiary contacts between the C-terminal and
the NAC and N-terminal regions of the protein [47,48]. Approximately 1/3 fraction of αS in neurons
adopts a partially folded α-helical structure [49] upon binding to membranes [50]. The functional
conformation of the protein, at least for its role in synaptic vesicle trafficking and neurotransmission
release, has been proposed to consist on α-helix-rich oligomers that are assembled on the cellular
membranes [49]. However, under pathological conditions, αS self-assembles into amyloid aggregates,
with the typical cross-β structure, which can ultimately form amyloid-rich inclusions.
The presence of these amyloid inclusions is the histopathological signature of a number of
neurodegenerative disorders collectively referred to as synucleinopathies [51,52]. The three major
synucleinopathies include Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA). PD is characterized by motor symptoms such as tremor at rest, slowness
of movement, and balance problems. Up to 80% of PD patients develop cognitive changes called
PD-dementia [53,54]. Patients with DLB initially present cognitive changes and hallucinations prior
to the development of parkinsonism. MSA is characterized by similar motor defects to PD as well
as cerebellar ataxia, and autonomic failure. MSA is more similar to prion diseases in that it rapidly
progresses and life expectancy is much shorter compared to PD. In addition, a significant proportion of
Alzheimer´s disease patients also have αS pathology, although in most cases restricted to the amygdala,
unlike synucleinopathies [55].
PD is the second most common form of neurodegeneration following Alzheimer´s disease. The
mean age of onset of the sporadic forms of the disease, which represent 90% of the cases, is approximately
65 years old. In the hereditary forms associated with the αS gene (SNCA), however, there is a much
earlier onset of the disease (the most potent mutation being the G51D) with a faster and more severe
progression of pathology [56–58]. αS gene (SNCA) duplication, triplication and polymorphisms also
cause PD [59–61]. Autosomal dominant inherited mutations in genes including LRRK2 and GBA cause
late onset PD with symptoms similar to sporadic PD, while autosomal recessive mutations in other
genes such as PINK1 cause early onset forms of parkinsonism [62,63]. LRRK2 and GBA pathological
mutations have been reported to increase the formation of αS inclusions [64–67]. It is important to note
that not all individuals with LRRK2 mutations show neuronal αS inclusions in postmortem brains,
and whether individuals with autosomal recessive mutations have αS pathology (typically referred
to as Lewy body pathology) remains questionable. The typical motor symptoms of the disease are a
consequence of the degeneration of dopaminergic neurons in the SNc in the basal ganglia of the brain
resulting in bradykinesia and rigidity [68]. In addition, there are neuropsychiatric symptoms that
occur at later stages, and other non-motor symptoms that have been recently suggested to occur at the
early stages of the disease [68].
αS inclusions inside neurons are referred to as Lewy bodies (LBs) and Lewy neurites (LNs) in
PD and DLB. In MSA, however, αS accumulates primarily into inclusions found in the cytosol of
oligodendrocytes, called glial cytoplasmatic inclusions, although a small percentage of neurons can also
have αS inclusions [51]. The aggregation of αS into amyloid aggregates is thought to play a key role in
the initiation and spreading of these diseases, although controversy remains whether LBs or smaller
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polymorphs of aggregates contribute to neuronal defects and toxicity. αS is not only pathologically
but also genetically linked to disease. Hereditary mutations in the SNCA gene or duplications and
triplications of the wild-type gene lead to autosomal dominant forms of PD and DLB, with an earlier
age of disease onset [59,69,70]. In these familial cases, accumulation of αS in LBs and LNs is also
observed [51,71], and the cases of triplications in the SNCA gene typically result in a more severe
disease progression than in the cases of gene duplication. In addition, a genome-wide association
study has shown that individuals with certain polymorphisms of the SNCA gene have a higher risk of
developing sporadic PD and MSA [60,72], and some of these polymorphisms have been linked to a
higher expression of αS in neurons [73]. Further, the injection of αS amyloid fibrils into the brains of
healthy mice induce αS inclusion formation and PD-like pathology [14,74,75].
The genetic evidence, along with the neuropathologic evidence for accumulation of αS in patients
with PD and other synucleinopathies, indicates a central role for αS in the pathogenesis of both the
inherited and sporadic forms of these diseases. Indeed, evidence suggests a mechanistic link between
even slightly higher levels of αS and the formation of αS amyloid aggregates within neurons and the
induction of neurodegeneration, likely through the generation and accumulation of toxic αS aggregated
species during the process of amyloid self-assembly [76,77].
3. α-Synuclein Aggregation Mechanisms and Pathways
The transition of a protein from its functional, typically monomeric state to the amyloid state is
a highly complex process that depends on both intrinsic features of the particular protein and the
environmental conditions. Early analysis of in vitro kinetics of formation of amyloid fibrils show
that the overall process includes a nucleation step (Figures 1 and 2A), where oligomeric species
and a sufficient number of fibril nuclei are formed, followed by an exponential step, reflecting the
nuclei-dependent growth through monomer addition, generating protofilaments and eventually
mature amyloid fibrils. This type of mechanism has been described by a nucleation-polymerization
model [78]. The typical sigmoidal kinetic profiles observed for amyloid formation were interpreted as
a greater ease of monomer addition onto already formed aggregates compared to the de novo formation
of aggregates directly from monomers through nucleation. Consequently, by adding preformed
fibrils to a monomeric solution, the nucleation step is bypassed, and the kinetic curves show only the
exponential growth step, typically reflecting the elongation process (Figure 2B). The growth of the
fibrils by monomer addition onto the fibrillar ends ensures that the structural properties adopted by
the newly added protein molecules are identical to those of the molecules of the fibrillar parents in
a phenomenon called templating [79], which is analogous to that observed in crystallization. More
complex models have been later developed for analyzing the amyloid aggregation mechanism of certain
amyloidogenic proteins. One such model is the so-termed nucleation-conversion-polymerization
model which includes a structural conversion of the early formed oligomers into β sheet-enriched,
elongation competent oligomers [80,81] (see Figure 1).
3.1. Primary Nucleation
Aggregation of αS is typically initiated in vitro by subjecting the protein solution to agitation,
either shaking or stirring [82]. Under diluted, highly hydrating conditions, at neutral pH and
physiological ionic strength and temperature, αS is not observed to aggregate for more than 7–10 days
of incubation without sample agitation. However, when the sample is strongly agitated, aggregation
is triggered within 1–3 days, depending on protein concentration and agitation speed. In those
conditions, nucleation initiates at the air/water interface or any other hydrophobic/hydrophilic interface
present in the sample, such as the hydrophobic coatings of sample containers or stirring bars,
by heterogeneous primary nucleation [83,84]. The role of agitation in promoting aggregation could
be altering and/or increasing the surface of the nucleation-active air/water interface, and increasing
the apparent elongation rate through the multiplication of growth-competent aggregate sites by
shearing-induced fibril fragmentation. Given the propensity of the N-terminal region of αS to acquire
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amphipathic α-helices, the protein preferentially partitions or adsorbs at hydrophobic/hydrophilic
interfaces, in order to simultaneously maximize the hydrophilic interactions in the aqueous environment
and the hydrophobic force at the hydrophobic surface [85]. At the interface, the protein initiates
self-assembly (under highly hydration conditions), likely as a result of the local increase in protein
concentration and the selection of nucleation-efficient conformations upon adsorption. This feature
has been indeed used to develop other strategies of inducing aggregation, such as the addition of
hydrophobic nanoparticles [86], or larger beads [87], or even lipid vesicles composed of particular
(typically non-physiological) types of phospholipids, which have resulted in good nucleation-active
surfaces [88,89]. Interestingly, this is not a unique property of αS, since hydrophobic/hydrophilic
interfaces have been found to be critical for the aggregation of many other amyloidogenic proteins and




Figure 2. Schematic representation of the different processes that can take place during amyloid fibril
formation. Oligomeric species, highlighted with circles for a better visualization, can be generated
through primary nucleation (A), but also through fibril disaggregation (D) or secondary nucleation
(E) processes. Fibril elongation (B) and fragmentation (C) are also represented.
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We have recently observed, however, that αS can form amyloid aggregates without the need
of a nucleation-active surface through homogeneous nucleation under limited hydration conditions,
and that when the protein undergoes this process, there is a preference for remarkably different
amyloid polymorphs. Specifically, there is a preference for an antiparallel β-sheet arrangement,
in contrast to the parallel β-sheet architecture adopted when heterogeneous nucleation dominates [92].
The formation of amyloid aggregates rich in intermolecular antiparallel β-sheets under limited
hydration conditions has been also reported for other amyloidogenic peptides, and a multitude of
a priori non-amyloidogenic proteins belonging to different structural classes, as well as disordered
peptides such as poly(L-lysine) [83,93–99].
The antiparallel intermolecular β-sheet structure has been also previously observed in stable,
particularly toxic oligomers of αS and other amyloidogenic systems and has been proposed to be
distinctive of these toxic species [100–103]. These oligomers have been suggested to be off-pathway by
some researchers. In the light of our new findings, they are, however, best described as on-pathway
of an amyloid aggregation process triggered by homogeneous nucleation under limited hydration
conditions. We noticed that a significant number of protocols to generate the stable antiparallel β-sheet
oligomers reported include a lyophilization step or the peptide/protein stock is lyophilized. These stable
oligomers represent a good model to investigate the structural and biological properties of pre-fibrillar
amyloid oligomers, bearing in mind that some of their properties might differ significantly from
those of the parallel β-sheet oligomeric intermediates generated under the typical in vitro aggregation
reactions (i.e., at the air/water interface), which are more difficult to trap.
One of the cellular microenvironments with a particularly low content of water (by definition) is
the interior of protein-rich droplets, generated by liquid-liquid phase separation (LLPS). These phase
separated protein droplets likely play a role in the in vivo aggregation of a number of amyloidogenic
proteins such as tau [104,105], TDP-43 [106,107] and αS [108,109]. Although the mechanism of the
liquid-to-solid transition of these protein droplets is unclear, our recent data on the amyloid aggregation
inside αS droplets generated in vitro suggest that the process is triggered by homogeneous primary
nucleation resulting in the formation of amyloid aggregates with a preference for an intermolecular
antiparallel β-sheet structure [92]. Whether this mechanism occurs in the liquid-to-solid transition of
αS droplets in vivo and can take place in other protein-rich droplets of other amyloidogenic proteins
needs to be explored.
3.2. Secondary Processes
In addition to primary nucleation (Figure 2A) and templating-based aggregate elongation
(Figure 2B), other process have been shown to be important in the overall amyloid aggregation
process, insofar they give raise to different αS self-assembled species, including fibril fragmentation,
disaggregation and fibril-catalyzed secondary nucleation [10,12,110–112]. Fibril fragmentation
(Figure 2C) implies the rupture of elongated fibrils into smaller fragments, thus resulting in the
multiplication of growth-competent fibrillar ends accessible for monomer addition. This can occur at
any phase of the self-assembly process [113] and significantly accelerates the apparent fibril growth
rate [12]. Prolonged exposure of fibrils to mechanical stress results in the decrease of their length
distribution toward a limit that is solely determined by the mechanical properties of the fibrils [114],
while maintaining their fibrillar nature. There is no evidence, therefore, that fibril fragmentation can
originate significant fractions of oligomeric species. This process is greatly enhanced by shear forces
such as those existing in typical αS in vitro aggregation setups, but its effect in vivo remains unclear.
Oligomeric species are typically assumed to be formed during primary nucleation (Figure 2A),
but they can also be generated through secondary processes. The release of αS oligomeric species
from fibril disaggregation (Figure 2D) has been observed in vitro upon dilution of fibrils [10,112,115],
with significant fractions of oligomeric species generated when the fibrils are at concentrations below
approximately 1 µM [10]. This process that has been observed in vitro, could be favored in the
cellular context through the disaggregation activity of chaperones (see Section 6) or other fibril
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destabilizing agents [30] and could be highly relevant in the cell-to-cell transfer if fibrils are released to
the extracellular space.
αS amyloid fibrils can be formed with a greatly reduced lag-phase duration by secondary
nucleation processes catalyzed at the surface of the amyloid fibrils (Figure 2E). This process implies
the de novo assembly of monomers onto the surface of pre-assembled aggregates and represents,
therefore, a particular type of heterogeneous nucleation. The aggregation of the Aβ42 peptide into
amyloid fibrils under typical physiological conditions in vitro has been shown to be dominated by
secondary nucleation processes, once primary nucleation has been triggered [116]. The consequence is
a significant amplification of the number of aggregates during the reaction, with the generation of
significant concentrations of toxic oligomers [32]. Therefore, secondary nucleation processes have
been suggested to play an important role in amyloid spreading in disease scenarios [110,117,118].
In the case of αS, secondary nucleation occurs at mildly acidic pH conditions (under highly hydration
conditions) [118], such as those present in endosomes and lysosomes in the cell, and its relevance
in vivo remains unknown.
3.3. Physicochemical Factors Affecting Amyloid Aggregation Process
A number of physicochemical factors in the solution conditions have been proposed to modulate
not only the rate but also the route of amyloid formation in αS and other amyloidogenic proteins
and peptides. Different amyloid polymorphs are accumulated upon slight variations in the solution
conditions of the aggregation reaction. Among all the factors, three appear to be key in αS: pH, ionic
strength and water activity. pH has been shown to modulate the relative rates of elongation and
secondary nucleation processes, which not only can affect the structure of the most populated amyloid
polymorphs, as explained below, but also the overall rate of aggregate multiplication and, therefore,
in vivo spreading [118]. The differences in ionic strength seem to affect primarily the folding and
packing of the fibrillar structure and thus the preference for a particular amyloid polymorph [119].
In addition, relatively high ionic strengths, including physiological concentrations, increase the
formation of higher-order assemblies of fibrils [118], an effect that might be relevant during LB
formation. Water activity and, therefore, the protein hydration state have been recently demonstrated
to be a key determinant not only for triggering αS self-assembly (maintaining αS monomeric and
preventing it from misfolding and self-assembly under highly hydration conditions), but also for
dictating the preference for the type of primary nucleation (heterogeneous vs homogeneous) and the
type of structural amyloid polymorph generated (parallel vs antiparallel β-sheet structure). Conditions
of very poor water activity such as those encountered inside protein-rich droplets, generated by LLPS,
have been reported to be particularly efficient in triggering αS amyloid aggregation both in vitro and
in vivo [105,108,109].
Depending on the microenvironment that αS encounters in the cell, therefore, alternative amyloid
aggregation mechanisms and pathways would be triggered, leading to the formation of remarkably
different amyloid polymorphs.
4. Multiplicity of α-Synuclein Aggregated Species
Two distinct major pools of protein aggregated species can be distinguished during the general
process of amyloid aggregation: soluble oligomers, and insoluble fibrillar species. Each of these pools,
however, encompasses an array of individual species both in terms of size and structure. In addition,
significant variability in terms of ultrastructure has been observed between amyloid aggregates, both in
terms of oligomers and fibrils, even if they have similar sizes and secondary structure contents [119,120].
4.1. Fibrillar Polymorphs
In the last few years, and with the great advances of solid-state nuclear magnetic resonance
(ssNMR) and cryo-electron microscopy (cryo-EM) techniques, a number of structures of different αS
fibril polymorphs generated in vitro with recombinant protein have been resolved at atomic resolution,
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and significant structural differences between the different fibril polymorphs have been observed.
In some structures the protofilament fold is similar, typically forming a Greek key structure [121,122],
with the differences arising in the packing of the protofilaments (the type of inter-protofilament
interactions and mutual disposition between protofilaments) (see Figure 3). Most of the reported
fibril structures contain the same central region of the protein as the amyloid core, including residues
35–100 [119,121–123]. The number and location of β-strands within this region, however, varies
between fibril polymorphs generated under different solution conditions, with the ionic strength,
the presence of polyanions or the pH of the solution as main factors for fibril structure variability.
These observations, therefore, already highlight the relevance of electrostatic interactions in the
intramolecular and intermolecular forces that define the overall structure in the different amyloid
polymorphs [119,124,125]. Two regions within the amyloid core have been suggested to be important
for stabilizing the amyloid structure [123], concretely 71–82 region, which was also found to be essential
for the initiation of the aggregation process [126], and 45–57 region, where most of the pathological
point mutations are located.
Figure 3. Structural features of αS fibrils. (A) Representative atomic force microscopy (AFM) and (B) 3D
cryo-EM reconstruction image of a sample of αS fibrils. Adapted from Figure 1B,C, Guerrero-Ferreira,
R. et al. 2018, eLife, published under the Creative Commons Attribution 4.0 International Public
License (CC BY 4.0; https://creativecommons.org/licenses/by/4.0/) [123]. (C) Summary of the structural
differences of αS fibril polymorphs resolved by cryo-EM. Reproduced from Figure 4, Guerrero-Ferreira,
R. et al. 2019, eLife, published under the Creative Commons Attribution 4.0 International Public License
(CC BY 4.0; https://creativecommons.org/licenses/by/4.0/) [119,120].
The large scale structural differences between amyloid polymorphs induced by small changes in
buffer conditions [119] highlights the large variability of structural rearrangements and interaction
networks able to stabilize an amyloid fold of the same protein. These different polymorphs have very
similar overall free energies, which results in a flat amyloid misfolding landscape with many local
minima. This landscape contrasts with the funnel-shaped landscape found for the folding of most
proteins, where the folded, native structure represents the lowest global energy minimum [127,128].
Indeed, the type of landscape of the amyloid conformation is the consequence of the type of interactions
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that stabilize this particular conformation, which are dominated by hydrogen bonds between the
main-chain atoms of the polypeptide chain [129]. The contributions of the interactions between side
chain groups to the overall energy of the amyloid structure are typically less relevant, although they
seem to be crucial for the definition of the type of amyloid polymorph preferred during the nucleation
step, which is ultimately defined by the solution conditions.
In this scenario, it would seem very plausible that alternative amyloid polymorphs could be
formed in different cellular types and perhaps in different microenvironments of the same cell.
If amyloid aggregation would be a favorable process, the consequences would be that multiple amyloid
polymorphs could co-exist even in the interior of the same cell. The large energetic barrier for primary
nucleation makes typically αS aggregation a kinetically unfavorable process (under highly hydration
conditions and in the absence of pre-formed fibrils). Once triggered, the faster rates of elongation
and secondary processes, as compared to the rate of primary nucleation [118], would result in the
prevalence of the polymorphs that multiply quicker, i.e., the system is typically governed by a kinetic
rather than a thermodynamic partitioning. If fragmentation and elongation are the preferred secondary
processes, then it could be possible that only one major type of polymorph dominates the amyloid
population, which would be defined by the initial type of interactions that are established during
primary nucleation. If, under other conditions, secondary nucleation is more favorable than elongation,
with rates comparable with that of primary nucleation, then various types of polymorphs could co-exist,
since the structure of the aggregates generated by secondary nucleation does not typically reflect
the structure of their fibrillar parents [130]. The structure of the aggregates generated by secondary
nucleation, in analogy to what is found for those formed under primary nucleation, depends mainly on
the solution conditions [130]. These are important points that are not always taken into consideration
when analyzing for example the structure of in vivo-generated amyloid aggregates by NMR or cryo-EM
after amplifying the number of aggregates by in vitro seeding reactions. In such seeding reactions,
secondary nucleation processes could be governing which would favor the formation of amyloid
aggregates with structures significantly different from those of the parent fibrils. The predominance
of one type of amyloid polymorph over others depends primarily, therefore, on the properties of
the protein microenvironment, as those dictate the structure of the pre-nucleus during primary and
secondary nucleation, as well as the relative rates of primary and secondary nucleation, and elongation.
The same molecular event of αS amyloid aggregation is associated with not only PD but also
other neurodegenerative disorders. In the particular case of MSA, the αS inclusions are localized in
different cellular types with respect to the other synucleinopathies, which suggests that, at least for this
disease, αS aggregation is likely triggered by an alternative mechanism to that associated with PD or
DLB. In agreement with this idea, pathological αS in glial cytoplasmatic inclusions or in LBs has been
reported to be conformationally and biologically distinct [17,35]. The intracellular environment is,
therefore, determinant for the accumulation of particular types of amyloid polymorphs. These results
are in line with earlier studies that suggested the existence of disease-specific αS amyloid polymorphs.
In a seminal study, injection of amyloid-like fibrillar structures derived from MSA patient´s brain
extracts into experimental animals induced neurodegeneration accompanied by αS deposition in all
cases. However, none of the animals inoculated with αS fibrillar species obtained from PD brains
developed neurological deficits [17,35]. Parallel studies were performed with in vitro-generated
amyloid polymorphs and showed the variety of seeding capacities and neurotoxic properties of the
different αS aggregated species analyzed [18,131]. Recently, the structure of αS inclusions extracted
from the putamen of deceased MSA patients was compared to those extracted from the cortex and
amygdala of deceased DLB patients by means of cryo-EM. All the MSA patients analyzed showed
very similar filament structures, which were very different from the filaments extracted from DLB
cases, and in both cases remarkably different from those that have been formed in vitro up to date with
recombinant proteins [132]. These findings highlight the urgent need to find αS aggregation conditions
in vitro that truly recapitulate the aggregation pathways triggered in vivo. Despite the similar amyloid
folds, two types of αS filament polymorphs in MSA brains were distinguished, being the so-called
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Type-II structure preferred in patients with a longer life span [132]. An interesting feature observed
in MSA patients’ brain derived fibrils was the presence of an additional molecule, of yet unknown
nature, that connects the two protofilaments in both Type I and Type II filaments [132]. This molecule
establishes electrostatic interactions with positively charged residues in αS, specifically the side chains
of residues K43, K45 and H50. These interactions might be strongly altered by the G51D and A53E
disease-associated αS mutations, which could lead to altered fibrillar structures and stabilities, which,
in turn, could be related to the characteristics of these hereditary forms: early disease onset, shorter
disease duration (compared to sporadic PD) and severe cognitive and psychiatric disturbances. Overall,
these findings are in line with the idea that different conformations of αS contribute to the type of
neurodegenerative disease as well as disease prognosis.
Along the most recent improvements regarding identifying and studying the variety of amyloid
polymorphs in synucleinopathies, protein misfolding cyclic amplification (PMCA) [133] together
with real-time quaking-induced conversion (RT-QuIC) [134] are providing highly valuable insights
into the characteristics of patient-derived αS aggregated species as well as helping to bring about
new diagnostic tools in the field of neurodegeneration [135]. Both techniques allow replicating and
amplifying the structure of abnormal αS by repeatedly fragmenting the parent aggregates and using
them as templates for seeding reactions with recombinant monomeric αS in the presence of the
thioflavin T probe. By comparing the seeding kinetics, important information about the seeding
efficiency of patient-derived or in vitro-generated amyloid polymorphs can be extracted. Both assays
have been used with fibrillar material extracted from brain or gastrointestinal tissue of PD, MSA
and DLB patients and the aggregates generated were demonstrated to faithfully recapitulate the
biochemical, structural and neurotoxic properties of the parent, in vivo-generated aggregates [136–142].
These assays can distinguish between cerebrospinal fluid samples from patients diagnosed with PD or
MSA [143], and are being further developed with the aim of using them as diagnostic and prognostic
tools for the distinct types of synucleinopathies.
4.2. Oligomeric Polymorphs
The process of amyloid fibril formation requires the transition of the protein by a series of multiple
oligomeric intermediates that differ in terms of size (from dimers to large assemblies containing
typically less than a hundred of protein units) and structure (from essentially disordered structures
similar to those of their monomer precursors to β-sheet rich structures close to that displayed in
the fully formed fibrillar state). The distinction between oligomers and short fibrils is not always
trivial and size alone might not be a good parameter for this. A distinctive characteristic of fibrils
is that they elongate from their ends by association of monomers from the solution and that the
elongated structures have the same structure and β-sheet content as their aggregate parents. In contrast,
the elongation of oligomers would result in more elongated structures with a significantly higher
β-sheet content. A critical parameter, therefore, for the definition of oligomers is the degree of β-sheet
content as compared to that of the fibrillar structures, which should be used in addition to the size of
the aggregates.
Given the multiplicity of types of oligomers in route to fibril formation and their inherent transient
intermediate nature in the process, their study and characterization have been proved to be extremely
challenging. Single-molecule techniques, however, have provided valuable information of such species.
Two structural groups of αS oligomers formed during the lag-phase of fibril formation under typical
in vitro reactions (i.e., under conditions of heterogeneous nucleation at the air/water interface) were
identified by single-molecule Förster resonance energy transfer [10]. The initially formed oligomers
present a diffuse, proteases sensitive and non-toxic structure (referred to as type-A oligomers). These
oligomers slowly convert into more compact and stable, protease resistant, toxic oligomers (referred to
as type-B oligomers), with partially-formed β-sheet structure. These oligomers elongate later through
monomer addition to form protofilaments and eventually mature fibrils (see Figure 1) [10,144]. In order
to study these different structural oligomeric forms further, we and others have developed strategies
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to prepare samples of analogous stable oligomeric forms that result in more than 90% of the sample
enriched in each particular type of oligomer. These oligomeric samples have been characterized in
detail and have been reported to be stable for days.
Figure 4. Structural features of two structurally different types of αS oligomers. Some of the most
detailed structural information on αS oligomers has been obtained by the use of enriched samples of
structurally homogeneous oligomeric species that have been trapped by the addition of molecules
that prevent the conversion of oligomers to fibrils (for example the molecule EGCG, that results in the
accumulation of type-A* oligomers) or the induction of alternative amyloid pathways by the modulation
of the solution conditions that result in the kinetic stabilization of oligomeric species (i.e., induction of
homogeneous nucleation under limited hydration conditions such as lyophilization, which results in
the formation of type-B* oligomers). (A,B) Typical morphology of type-A* oligomers (A) and type-B*
oligomers (B) probed by AFM. (C,D) Structural models of type-A* oligomers (C) and type-B* oligomers
(D) according to the information obtained from solution and ssNMR data (from Fusco et al., Science
2017, reprinted with permission from AAAS) [145]. (E) Morphology and 3D-reconstruction models of
type-B* oligomers according to cryo-EM image analysis (reprinted from Chen et al., PNAS 2015) [103].
The strategy used to prepare samples enriched in a type of oligomers analogous to type-B
oligomers consists in inducing the aggregation of the protein through a particular amyloid pathway
at dehydrating conditions (i.e., during lyophilization), under which homogeneous nucleation is
favored [92]. This pathway results in the accumulation of kinetically trapped, antiparallel β-sheet, toxic
oligomers whose rates of disaggregation into monomers and elongation into fibrils are extremely slow.
These oligomers were referred to as type-B* oligomers to remark that they are analogous to type-B
oligomers but not exactly the same, as type-B oligomers are generated during the heterogeneous primary
nucleation of parallel β-sheet amyloid fibrils [103]. Despite the differences in the β-sheet arrangement
of the amyloid structure between type-B and type-B*oligomers, they are similar in a number of
features, reflecting their analogous nature. Both types of oligomers have similar sizes, an intermediate
secondary structure between the monomeric and the fully-formed mature fibrils, similar affinities
for lipid membranes and similar toxic mechanisms, with apparently identical cellular dysfunction
effects [10,26,27,103,145]. One remarkable difference is their ability to elongate: while type-B oligomers
quickly elongate into fully-formed fibrils, type-B* oligomers have their elongation abilities disrupted,
likely as a result of the antiparallel intermolecular β-sheet structure. Other amyloid-like aggregates
with an antiparallel β-sheet structure show a preference for small aggregates rather than the typical
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parallel β-sheet amyloid aggregates with long fibrillar morphologies [92]. Therefore, caution is needed
when extrapolating to the type-B oligomers the biological effects identified for type-B*, or the analogous
situation in other amyloidogenic proteins or peptides. Both types of oligomers seem to behave similarly
in terms of induction of toxicity, but in terms of seeding properties, and therefore spreading capabilities,
they behave very differently.
In the case of the oligomers analogous to type-A, formed during the heterogeneous primary
nucleation of the protein, the stabilization strategy consisted in using a molecule (epigallocatechin
gallate, EGCG) that binds to this structural type of oligomer and prevents its structural conversion
and progression into type-B oligomers and eventually amyloid fibrils [145]. We referred to these
oligomers trapped by the action of an inhibitor molecule that remains bound to the aggregates as
type-A* oligomers to reflect the fact that they consist on a complex between type-A oligomers and
several molecules of EGCG. Additionally, EGCG has been shown to modify chemically αS but without
major effects on oligomer formation [146]. Both type-A and type-A* oligomers have similar sizes,
have a disordered structure and are benign to the cells [10,145], but the presence of several molecules
of EGCG in the surface of the oligomer might affect some properties with respect to the unbound
oligomer form.
Both type-A* and type-B* oligomers have similar size distributions, with the majority of the species
showing sizes of ca. 15–40-mers (for the type-B* oligomers an average of ca. 30 protein molecules was
estimated) [103,145]. The vast majority of the species in both samples present a rather homogeneous
structure: essentially disordered in the case of type-A* oligomers, and with a β-sheet core composed of
70–88 residues in the case of type-B* oligomers. Indeed, the structural homogeneity of both oligomeric
samples have allowed their structural characterization by ssNMR [145] and the 3D cryo-EM structural
reconstruction in the case of type-B* oligomers (at 18-Å resolution) [103] (see Figure 4). The structural
reconstruction by cryo-EM showed that the oligomers presented a cylindrical morphology, similar
to that previously reported for toxic prefibrillar oligomers [147], with a diameter of ca. 10 nm, that
coincide with the diameter found for αS mature fibrils. However, in contrast to the αS fibrils whose
structure has been determined up to date, these oligomers show a hollow core, suggesting that the
interactions between β-sheets are predominantly hydrophilic and mediated by water molecules. This
structural arrangement results in a significant fraction of hydrophobic residues exposed to the solvent at
the surface of the oligomer structure [103], which explains the particular ability of this type of oligomer
to interact with the interior of the lipid bilayers of cellular membranes and disrupt membrane integrity,
leading to the toxic consequences for the cell [145]. Similar water-mediated protofilament interactions
with the concomitant formation of fibrils with a hollow-core have been reported for other amyloidogenic
polypeptides related to disease [5,8,148]. In the case of αS fibrils, all the structures obtained by cryo-EM
analysis and composed of multiple protofilaments (typically two) show a hydrophobic interface
between protofilaments that is stabilized by a few ionic salt bridges. This protofilament arrangement
results in most of the hydrophobic residues of the protein buried in the interior of the mature fibrils
and a fibrillar surface mostly hydrophilic. In contrast, a highly hydrophobic fibrillar surface is inferred,
indeed similar to that of the type-B* oligomers, when the nature of the solvent exposed surface of
analogous fibrils was analyzed and compared with monomeric and Type-A* oligomers using the
8-anilino-1-naphthalene sulfonate (ANS) probe [103,149]. This apparent contradiction needs to be
resolved, as the solvent-exposed hydrophobic surface seems to be highly correlated with toxicity in
amyloid aggregates [150].
OtherαS oligomeric structures that have been reported to be formed during fibril formation include
annular oligomers, as visualized by transmission electron microscopy (TEM) and AFM [151,152], but not
further structural determination was reported for such oligomers and their relationships with the
fibrillar structures and other types of oligomers remain unknown. Oligomeric forms generated during
fibril formation have been isolated, in some cases purified by gel filtration, and remain stable under a
variety of conditions, which allowed certain structural and mechanistic characterization [101,153–156],
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with some features, such as size (average of 29–31 monomers per oligomer), antiparallel β-sheet
structure [101] and amyloid core regions [153], reminiscent to those of the type-B* oligomers.
A large number of αS oligomeric species have been described as a result of their stabilization by
particular types of molecules able to either bind to or covalently modify αS, such as selegiline [153],
baicalein [157,158] or dopamine and its analogs [159,160]. Although significant differences in
morphology, size and secondary structure for the different αS oligomeric species have been shown,
a general trend is observed. Most of the reported stabilized oligomers were either mainly disordered,
which were generally reported to be nontoxic to neuronal cells, or presented certain, but limited,
β-sheet structure, which showed significant level of toxicity in cells [120], suggesting that these two
main types of oligomers could be general to the various αS aggregation pathways that have been
explored up to date.
5. Possible Roles of α-Synuclein Species in Cell Toxicity
Aberrant folding and aggregation of certain amyloidogenic proteins has been suggested to be the
initial trigger of amyloid diseases, later followed by a cascade of events such as calcium and metal ion
dyshomeostasis, oxidative stress and proteostasis impairment. This initial trigger has been related with
the ability of certain aggregated species to bind and disrupt cellular membranes. Amyloid aggregates
from different proteins and peptides, including some not related a priori with human diseases, have
been shown to induce cellular toxicity by similar mechanisms of membrane perturbation [161,162].
These experimental observations suggested that this mechanism of toxicity is indeed a common feature
for this type of aggregates that share the same toxic structural determinants [1,13]. While the intrinsic
toxic properties of the aggregates are independent of cellular proteostasis, their accumulation and life
span strongly depends on the cellular proteostasis activity [163].
The nature of the most toxic aggregated species formed during amyloid aggregation, in particular
for αS, remains a subject of intense debate in the field. Both oligomers and fibrils have been shown to
be toxic in different contexts and comparative studies have reported contradictory results, although
the nature of the aggregates, particularly for the oligomeric species, is generally not defined with
the precision required to derive strong conclusions. There is multiple experimental evidence for an
important role of particular types of oligomers in αS amyloid toxicity. Structural-toxicity studies
on in vitro-generated αS oligomers have generally shown that disordered oligomers are benign to
cells, while oligomers with partially formed β-sheet cores and highly hydrophobic surfaces are the
most inherently toxic αS species upon exposure to cells [120]. While these studies were performed
with in vitro-generated αS aggregates, similar cellular effects were observed in a human iPS-derived
αS triplication neuronal model with endogenous αS aggregation, suggesting that analogous types
of αS aggregated species are also formed in vivo [26,27]. The ability of the rudimentary cross-β
oligomers to induce toxicity has been proposed to arise, at least in part, from their ability to bind
lipid membranes and insert their flexible, hydrophobic β-sheet core into the interior of the lipid
bilayer [145]. The combination of these structural features is absent in the monomeric and early
disordered oligomeric forms [145,164], as well as in the highly rigid (in some cases with rigidities close
to steel [165]) fibrillar structure. The insertion of this type of oligomers into the lipid membranes causes,
then, a cascade of toxic effects in the cells such as calcium and metal ion imbalance, oxidative stress,
mitochondrial and lysosomal dysfunction, and eventually cell death [26,27,166–169]. In addition,
the exposure of hydrophobic residues and hydrogen-bond unsatisfied amino acid groups on the surface
of these inherently intermediate, partially folded species, likely result in the aberrant and promiscuous
interaction of these species with other proteins and cellular components that could disrupt their
correct biological functions. This situation would explain some of the reported cellular effects of αS
oligomers such as synaptosomal and mitochondria dysfunction [170,171] and the impairment of the
ubiquitin-proteasomal systems [172,173].
Although αS fibrillar aggregates are able to bind to cellular membranes, they appear to remain
bound to the membrane without inserting their β-sheet core into the lipid membrane, in contrast to the
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toxic β-sheet oligomers [145] and, consequently, their effects on membrane perturbation are milder in
terms of mass concentration, unless a massive overload of fibrils are bound to the same cell at the same
time. However, similar qualitative effects, such as intracellular ion homeostasis perturbation [174] and
cellular proteostasis [173], mitochondria [175] and lysosome dysfunction [176], have been observed for
both fibrillar and β-sheet oligomers, suggesting possible common mechanisms of toxicity between
oligomeric and fibrillar species. Recent evidence shows that distinct fibrillar αS polymorphs cluster at
the plasma membrane of neurons to a clearly different extent, and also exhibit different seeding abilities.
These results were interpreted in terms of variations in the organization of membrane receptors induced
by distinctive types of αS fibrillar polymorphs [177]. In some reports, αS fibrils have been shown to
induce an inflammatory response [178,179], although further studies are required to elucidate the role
of αS aggregates on the induction of a chronic inflammation, proposed to be an important factor in
triggering neurodegeneration.
6. Possible Roles of α-Synuclein Species in Cell-to-Cell Propagation
Misfolded forms of αS, and other proteins associated with neurodegenerative disorders, have
been shown to self-propagate and spread between interconnected regions of the central nervous system
acting as infectious agents propagating neurodegeneration, in a similar manner as it has been described
for prions [179]. The spatiotemporal progression of αS pathology and the progressive nature of PD
and other synucleinopathies [179] suggests the presence of specific anatomic αS spreading pathways.
Cell-to-cell transmission of αS aggregates has been experimentally observed [179] and more
directly evidenced in grafted fetal mesencephalic neurons in PD patients after a host-to-graft αS
misfolded transmission [180,181]. Indeed, the αS pathology transmission model has been used to
develop cell and animal models of αS pathology as the exposure of neurons to extracellular pre-formed
αS fibrils induces intracellular endogenous inclusions resembling those found in disease brains, the loss
of dopaminergic neurons in the SNc and the associated motor-behavior defects, recapitulating the core
features of PD [75].
We recently published a study that compared the ability of short (50 nm) fibrils and
seeding-incompetent oligomers (type-B* oligomers) to cause PD-related phenotypes in mice. Striatal
injections of short fibrils or elongation-deficient oligomers caused loss of dopamine neurons in the
SNc [75]. The short fibrils caused also recruitment of endogenous αS into pS129-positive inclusions
that resembled LB pathology, loss of dopamine terminals in the striatum, and induction of motor
behavior phenotypes. However, the seeding-incompetent oligomers caused some loss of dopamine
neurons in the SNc, reflecting their toxicity, but they did not produce αSyn inclusions or behavioral
phenotypes. Short amyloid fibrils, and likely elongation-efficient oligomers (type-B oligomers) that can
recruit and corrupt endogenous αS, are responsible for the majority of these phenotypes. Long fibrils,
however, were unable to internalize efficiently and therefore spread from cell to cell. These results
highlight the role of the size of the amyloid aggregates in the induction of intraneuronal αS inclusions,
and suggest a potential toxic effect of those processes that could occur in the cell and result in the
accumulation of small amyloid-like aggregates, such as fibril fragmentation, fibril disaggregation or
uncompleted aggregation. One example is the action of the Hsp70 chaperone disaggregation system
that has been reported to be able to either reduce αS aggregation and spreading [182] or enhance αS
amyloid aggregation by releasing spread-competent αS species [182]. The in vitro Hsp70-mediated
disaggregation of αS fibrils results primarily in the release of monomeric protein units from the fibrillar
ends [182]. Under optimal conditions (optimal chaperone-to-co-chaperone ratios and ATP availability),
the chaperone system is highly efficient and, therefore, the lifetime of possible toxic intermediate
species generated during the disaggregation process (either very short fibrils or oligomers) would be
very short and the overall Hsp70 system disaggregation activity would be beneficial to eliminate αS
toxicity [182]. However, if the disaggregation process is not completed because some of the components
of the chaperone complex are not optimal or the ATP availability is very limited at some point of the
reaction in the cell, this could result in the transient generation of toxic short fibrils and oligomers which
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could then diffuse and cause aberrant interactions with cellular components and spread efficiently
from cell to cell, as proposed in [183].
Disease-related familial mutations could alter the population distribution of amyloid polymorphs,
which could be related with their potential contribution to the pathogenesis [122,125]. Initial cryo-EM
structures of WT αS fibrils indicated that at least four of the five mutation sites found in familiar PD
(E46K, A53T/E, G51D and H50Q) are preferentially located at the protofilament interfaces, rather than at
the kernel of the amyloid structures. The presence of such mutations were suggested to affect severely
the protofilament arrangement and then the stability of mature fibrils, which was correlated with the
potential increase in the fraction of toxic oligomeric species within the cells [125]. The E46K pathological
mutation, however, was later reported to adopt a significantly different amyloid fold as compared to
the amyloid structure adopted by the WT protein at similar conditions [124,125]. The acquisition of this
alternative fibril kernel conformation by the E46K mutation results in a significantly higher propensity
to seed the formation of new fibrils as compared to the WT fibrils [124,125], which could influence the
speed of αS pathology spreading. It is interesting to note that the E46K mutation seems to be the only
hereditary αS mutation that manifests in a clinical picture closer to DLB; the other mutations being
more associated to PD.
7. Post-Translational Modifications
αS has a number of PTMs, with phosphorylation, ubiquitination and nitration highly related to
pathology [184]. Phosphorylation has been identified on various serine and tyrosine residues, mostly
located at the C-terminal region of the protein. Despite being the most PTM studied in αS, its role in
physiology and disease remain controversial [185]. Phosphorylation on serine 87 (pS87-αS), in the NAC
region, appears to be increased in PD brains but, paradoxically, reduces the membrane-interaction
ability and blocks αS fibril formation in vitro [186]. Other studies using a rat model, however,
point toward a neuroprotective effect of pS87-αS [187]. The phosphorylation of some residues such
as tyrosine 125 (p125-αS) has been reported to have a beneficial role regarding neurotoxicity [188],
while the same modification at serine 129 (pS129-αS) is indicative of pathology. It has been found
that more than 90% of the αS in the LBs of PD patients´ brains is phosphorylated at serine 129 [184],
while only ca. 4% in healthy brains [184]. This particular PTM has been shown to increase the rate of
αS amyloid aggregation [184], as well as the toxicity associated with this process [189]. Although other
studies have suggested a protective role based on its influence in reducing αS membrane binding [190]
and increasing the conformational flexibility of the monomeric protein (which would prevent fibril
formation) [191]. In the same line, constitutively expressed pS129-αS did not induce neurotoxicity in
an overexpression rat model, while non-phosphorylated αS did [192].
Another important type of PTM in αS is the ubiquitination of lysine residues located at the
N-terminal region of the protein. This region typically falls outside the amyloid core, although its
ubiquitination has been observed to inhibit amyloid formation [193]. Significant steric repulsions for
amyloid formation and structural differences in the fibrils would be expected upon ubiquitination in
this region of the protein given the size of ubiquitin with respect to that of the αS. Indeed, this PTM
can occur downstream fibril formation, given that most of the lysine residues of the N-terminal region
are exposed to the solvent and readily accessible for ubiquitination according to the currently available
cryo-EM structures [194].
Nitration of certain tyrosine residues are also commonly observed in pathologically relevant αS
inclusions and in some cases, such as nitration of tyrosine 39, have been reported to stabilize soluble
oligomeric species via dityrosine crosslinking [195].
The only available atomic structure of a post-translationally modified αS fibril carries the
N-terminally acetylated modification, and no differences with the unmodified protein fibrils were
observed [122]. This PTM is a mild modification located at a very distant region of the amyloid core in
the amyloid fibrils. It would be relevant to determine the influence of other PTMs, particularly those
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related to pathology, on the stability and structure of the αS oligomers and fibrils and their effect on cells,
as well as to define whether these modifications occur primarily before or after αS oligomerization.
8. Summary
It is gradually being accepted in the field that certain types of soluble oligomeric species of
αS are more inherently toxic than larger fibrillar aggregates. These oligomers can be generated
de novo from cytosolic αS or αS associated with membranes. However, recent experimental evidence
shows that fibrils and large intracellular inclusions can also be a source of soluble oligomers by fibril
disaggregation [10] and secondary nucleation processes [32], which could explain, at least in part, the
similarities in the toxic effects observed between oligomeric and fibrillar species. Mutations in αS that
destabilize the dimeric interface of mature fibrils, such as the pathological mutations H50Q, G51D and
A53T/V/E, may lead to a larger population of soluble toxic oligomers. However, these mutations are
extremely rare, so understanding the cellular mechanisms which favorβ-sheet oligomer formation need
to be further elucidated. These can include: slight increases in αS levels, defects in lysosome activity,
oxidation and PTMs that can occur particularly in dopamine neurons, induction of the formation of
intracellular αS droplets by LLPS, aberrant activity of chaperone systems or expression of other mutant
genes that can impact any of the above processes. Templated recruitment of endogenous αS also occurs
and, for this, particularly short fibrils appear to be the most potent αS species [75]. Multiple types of
aggregates are, therefore, populated during the process of self-assembly and might be involved in
different stages of the development of pathology, some species being directly involved in the induction
of neurotoxicity and others in the propagation of pathology [77].
A combination of three parameters appear to be key for the potential toxicity of αS aggregates,
and likely aggregates from other amyloidogenic proteins: size, a highly exposed hydrophobic surface,
and structural flexibility. Recent experimental evidence of remarkably different seeding capabilities of
structurally alternative amyloid polymorphs suggests that other structural properties play also a role
in αS aggregate toxicity. Further studies on structure-toxicity relationships on different αS aggregate
polymorphs will help to define the molecular basis of toxicity and spreading in αS aggregates. It is
important to identify also the structural determinants in the aggregates that dictates the preference for
the recruitment of monomeric molecules either at the ends of the fibrillar structure or at its longitudinal
surface and, thus, for the type of secondary process that governs the system, as this is an important
source of polymorph variability. Further experimentation is required to (i) elucidate the detail structure
of soluble toxic oligomers and the polymorphism associated with this type of αS species, (ii) how
solution conditions, pathological mutations and PTMs impact on their structure and stability and
(iii) the type of oligomer and fibril polymorphs that form in vivo in a disease-related context and that
could be associated with the distinct types of synucleinopathies. The type of αS fibril polymorphs
isolated from patient-derived brain samples are remarkably different from the fibril polymorphs
that up to date have been generated in vitro and whose structures have been characterized [132,196].
It would be relevant to characterize the structural types of αS oligomers and fibrils that are formed in
alternative conditions, and therefore through alternative amyloid pathways, to those explored in vitro.
In particular, those generated through liquid-to-solid transitions inside αS droplets generated by LLPS,
which have been recently suggested to precede αS amyloid formation in vivo, and that are likely to
occur through very different amyloid mechanisms to those of the typical processes studied in vitro
under diluted and highly hydrated conditions [92]. Gaining a better understanding of the type of
amyloid pathways and primary and secondary processes occurring in vivo, as well as the nature and
structure of the types of polymorphs of oligomers and fibrils formed, will help not only to identify the
molecular basis of αS aggregation in disease, but also to design future treatments and develop new
diagnostic tools for the early diagnosis of distinct types of synucleinopathies.
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143. Calabrese, C.; Davidson, N.R.; Demircioğlu, D.; Fonseca, N.A.; He, Y.; Kahles, A.; Lehmann, K.-V.; Liu, F.;
Shiraishi, Y.; Soulette, C.M.; et al. Genomic basis for RNA alterations in cancer. Nature 2020, 578, 129–136.
[CrossRef] [PubMed]
144. Iljina, M.; Garcia, G.A.; Horrocks, M.H.; Tosatto, L.; Choi, M.L.; Ganzinger, K.A.; Abramov, A.Y.; Gandhi, S.;
Wood, N.W.; Cremades, N.; et al. Kinetic model of the aggregation of alpha-synuclein provides insights into
prion-like spreading. Proc. Natl. Acad. Sci. USA 2016, 113, E1206–E1215. [CrossRef] [PubMed]
145. Fusco, G.; Chen, S.W.; Williamson, P.T.F.; Cascella, R.; Perni, M.; Jarvis, J.A.; Cecchi, C.; Vendruscolo, M.;
Chiti, F.; Cremades, N.; et al. Structural basis of membrane disruption and cellular toxicity by a-synuclein
oligomers. Science 2017, 358, 1440–1443. [CrossRef] [PubMed]
146. Palhano, F.L.; Lee, J.; Grimster, N.P.; Kelly, J.W. Toward the molecular mechanism(s) by which EGCG
treatment remodels mature amyloid fibrils. J. Am. Chem. Soc. 2013, 135, 7503–7510. [CrossRef]
147. Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon, M.; Nowak, R.J.; Walz, T.; Lansbury, P.T.J. Alpha-synuclein,
especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils.
J. Mol. Biol. 2002, 322, 1089–1102. [CrossRef]
148. Zhang, R.; Hu, X.; Khant, H.; Ludtke, S.J.; Chiu, W.; Schmid, M.F.; Frieden, C.; Lee, J.-M. Interprotofilament
interactions between Alzheimer’s Abeta1-42 peptides in amyloid fibrils revealed by cryoEM. Proc. Natl.
Acad. Sci. USA 2009, 106, 4653–4658. [CrossRef]
149. Celej, M.S.; Jares-Erijman, E.A.; Jovin, T.M. Fluorescent N-Arylaminonaphthalene Sulfonate Probes for
Amyloid Aggregation of α-Synuclein. Biophys. J. 2008, 94, 4867–4879. [CrossRef]
150. Mannini, B.; Mulvihill, E.; Sgromo, C.; Cascella, R.; Khodarahmi, R.; Ramazzotti, M.; Dobson, C.M.; Cecchi, C.;
Chiti, F. Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity.
ACS Chem. Biol. 2014, 9, 2309–2317. [CrossRef]
151. Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T.J. Neurodegenerative disease: Amyloid pores
from pathogenic mutations. Nature 2002, 418, 291. [CrossRef] [PubMed]
152. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T.J. Acceleration of
oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to
early-onset Parkinson’s disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 2000,
97, 571–576. [CrossRef]
153. Paslawski, W.; Mysling, S.; Thomsen, K.; Jørgensen, T.J.D.; Otzen, D.E. Co-existence of two different
α-synuclein oligomers with different core structures determined by hydrogen/deuterium exchange mass
spectrometry. Angew. Chem. Int. Ed. Engl. 2014, 53, 7560–7563. [CrossRef] [PubMed]
154. Lorenzen, N.; Nielsen, S.B.; Buell, A.K.; Kaspersen, J.D.; Arosio, P.; Vad, B.S.; Paslawski, W.; Christiansen, G.;
Valnickova-Hansen, Z.; Andreasen, M.; et al. The role of stable α-synuclein oligomers in the molecular
events underlying amyloid formation. J. Am. Chem. Soc. 2014, 136, 3859–3868. [CrossRef]
155. Giehm, L.; Svergun, D.I.; Otzen, D.E.; Vestergaard, B. Low-resolution structure of a vesicle disrupting
α-synuclein oligomer that accumulates during fibrillation. Proc. Natl. Acad. Sci. USA 2011, 108, 3246–3251.
[CrossRef]
156. Gallea, J.I.; Celej, M.S. Structural insights into amyloid oligomers of the Parkinson disease-related protein
α-synuclein. J. Biol. Chem. 2014, 289, 26733–26742. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8043 25 of 27
157. Hong, D.-P.; Fink, A.L.; Uversky, V.N. Structural characteristics of alpha-synuclein oligomers stabilized by
the flavonoid baicalein. J. Mol. Biol. 2008, 383, 214–223. [CrossRef]
158. Zhu, M.; Rajamani, S.; Kaylor, J.; Han, S.; Zhou, F.; Fink, A.L. The flavonoid baicalein inhibits fibrillation
of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 2004, 279, 26846–26857. [CrossRef]
[PubMed]
159. Lee, H.-J.; Baek, S.M.; Ho, D.-H.; Suk, J.-E.; Cho, E.-D.; Lee, S.-J. Dopamine promotes formation and secretion
of non-fibrillar alpha-synuclein oligomers. Exp. Mol. Med. 2011, 43, 216. [CrossRef] [PubMed]
160. Pham, C.L.L.; Leong, S.L.; Ali, F.E.; Kenche, V.B.; Hill, A.F.; Gras, S.L.; Barnham, K.J.; Cappai, R. Dopamine
and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway
aggregation of alpha-synuclein in a pH-dependent manner. J. Mol. Biol. 2009, 387, 771–785. [CrossRef]
[PubMed]
161. Glabe, C.G.; Kayed, R. Common structure and toxic function of amyloid oligomers implies a common
mechanism of pathogenesis. Neurology 2006, 66, S74–S78. [CrossRef]
162. Chiti, F.; Dobson, C.M. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress
Over the Last Decade. Annu. Rev. Biochem. 2017, 86, 27–68. [CrossRef] [PubMed]
163. Labbadia, J.; Morimoto, R.I. The biology of proteostasis in aging and disease. Annu. Rev. Biochem. 2015, 84,
435–464. [CrossRef] [PubMed]
164. Fusco, G.; De Simone, A.; Gopinath, T.; Vostrikov, V.; Vendruscolo, M.; Dobson, C.M.; Veglia, G. Direct
observation of the three regions in α-synuclein that determine its membrane-bound behaviour. Nat. Commun.
2014, 5, 3827. [CrossRef] [PubMed]
165. Smith, J.F.; Knowles, T.P.J.; Dobson, C.M.; Macphee, C.E.; Welland, M.E. Characterization of the nanoscale
properties of individual amyloid fibrils. Proc. Natl. Acad. Sci. USA 2006, 103, 15806–15811. [CrossRef]
166. Hoffmann, A.-C.; Minakaki, G.; Menges, S.; Salvi, R.; Savitskiy, S.; Kazman, A.; Vicente Miranda, H.;
Mielenz, D.; Klucken, J.; Winkler, J.; et al. Extracellular aggregated alpha synuclein primarily triggers
lysosomal dysfunction in neural cells prevented by trehalose. Sci. Rep. 2019, 9, 544. [CrossRef]
167. Volles, M.J.; Lansbury, P.T.J. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to
Parkinson’s disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002, 41, 4595–4602.
[CrossRef]
168. Stefanovic, A.N.D.; Stöckl, M.T.; Claessens, M.M.A.E.; Subramaniam, V. α-Synuclein oligomers distinctively
permeabilize complex model membranes. FEBS J. 2014, 281, 2838–2850. [CrossRef]
169. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.;
Kostka, M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci.
2007, 27, 9220–9232. [CrossRef]
170. Prots, I.; Grosch, J.; Brazdis, R.-M.; Simmnacher, K.; Veber, V.; Havlicek, S.; Hannappel, C.; Krach, F.;
Krumbiegel, M.; Schütz, O.; et al. α-Synuclein oligomers induce early axonal dysfunction in human
iPSC-based models of synucleinopathies. Proc. Natl. Acad. Sci. USA 2018, 115, 7813–7818. [CrossRef]
171. Ludtmann, M.H.R.; Angelova, P.R.; Horrocks, M.H.; Choi, M.L.; Rodrigues, M.; Baev, A.Y.; Berezhnov, A.V.;
Yao, Z.; Little, D.; Banushi, B.; et al. α-synuclein oligomers interact with ATP synthase and open the
permeability transition pore in Parkinson’s disease. Nat. Commun. 2018, 9, 2293. [CrossRef] [PubMed]
172. Emmanouilidou, E.; Stefanis, L.; Vekrellis, K. Cell-produced alpha-synuclein oligomers are targeted to, and
impair, the 26S proteasome. Neurobiol. Aging 2010, 31, 953–968. [CrossRef] [PubMed]
173. Lindersson, E.; Beedholm, R.; Højrup, P.; Moos, T.; Gai, W.; Hendil, K.B.; Jensen, P.H. Proteasomal inhibition
by alpha-synuclein filaments and oligomers. J. Biol. Chem. 2004, 279, 12924–12934. [CrossRef] [PubMed]
174. Bousset, L.; Pieri, L.; Ruiz-Arlandis, G.; Gath, J.; Jensen, P.H.; Habenstein, B.; Madiona, K.; Olieric, V.;
Böckmann, A.; Meier, B.H.; et al. Structural and functional characterization of two alpha-synuclein strains.
Nat. Commun. 2013, 4, 2575. [CrossRef]
175. Wang, X.; Becker, K.; Levine, N.; Zhang, M.; Lieberman, A.P.; Moore, D.J.; Ma, J. Pathogenic alpha-synuclein
aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathol. Commun.
2019, 7, 41. [CrossRef]
176. Flavin, W.P.; Bousset, L.; Green, Z.C.; Chu, Y.; Skarpathiotis, S.; Chaney, M.J.; Kordower, J.H.; Melki, R.;
Campbell, E.M. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins.
Acta Neuropathol. 2017, 134, 629–653. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8043 26 of 27
177. Shrivastava, A.N.; Bousset, L.; Renner, M.; Redeker, V.; Savistchenko, J.; Triller, A.; Melki, R. Differential
Membrane Binding and Seeding of Distinctα-Synuclein Fibrillar Polymorphs. Biophys. J. 2020, 118, 1301–1320.
[CrossRef]
178. Peralta Ramos, J.M.; Iribarren, P.; Bousset, L.; Melki, R.; Baekelandt, V.; Van der Perren, A. Peripheral
Inflammation Regulates CNS Immune Surveillance Through the Recruitment of Inflammatory Monocytes
Upon Systemic α-Synuclein Administration. Front. Immunol. 2019, 10, 80. [CrossRef]
179. Gustot, A.; Gallea, J.I.; Sarroukh, R.; Celej, M.S.; Ruysschaert, J.-M.; Raussens, V. Amyloid fibrils are the
molecular trigger of inflammation in Parkinson’s disease. Biochem. J. 2015, 471, 323–333. [CrossRef]
180. Kordower, J.H.; Brundin, P. Lewy body pathology in long-term fetal nigral transplants: Is Parkinson’s disease
transmitted from one neural system to another? Neuropsychopharmacology 2009, 34, 254. [CrossRef]
181. Li, J.-Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.;
Björklund, A.; et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft
disease propagation. Nat. Med. 2008, 14, 501–503. [CrossRef] [PubMed]
182. Taguchi, Y.V.; Gorenberg, E.L.; Nagy, M.; Thrasher, D.; Fenton, W.A.; Volpicelli-Daley, L.; Horwich, A.L.;
Chandra, S.S. Hsp110 mitigates α-synuclein pathology in vivo. Proc. Natl. Acad. Sci. USA 2019, 116,
24310–24316. [CrossRef] [PubMed]
183. Tittelmeier, J.; Sandhof, C.A.; Ries, H.M.; Druffel-Augustin, S.; Mogk, A.; Bukau, B.; Nussbaum-Krammer, C.
The HSP110/HSP70 disaggregation system generates spreading-competent toxic α-synuclein species. EMBO
J. 2020, 39, e103954. [CrossRef] [PubMed]
184. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.;
Iwatsubo, T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4, 160–164.
[CrossRef]
185. Xu, Y.; Deng, Y.; Qing, H. The phosphorylation of α-synuclein: Development and implication for the
mechanism and therapy of the Parkinson’s disease. J. Neurochem. 2015, 135, 4–18. [CrossRef]
186. Paleologou, K.E.; Oueslati, A.; Shakked, G.; Rospigliosi, C.C.; Kim, H.-Y.; Lamberto, G.R.; Fernandez, C.O.;
Schmid, A.; Chegini, F.; Gai, W.P.; et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits
alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 2010, 30,
3184–3198. [CrossRef]
187. Oueslati, A.; Paleologou, K.E.; Schneider, B.L.; Aebischer, P.; Lashuel, H.A. Mimicking phosphorylation at
serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of
Parkinson’s disease. J. Neurosci. 2012, 32, 1536–1544. [CrossRef]
188. Chen, L.; Periquet, M.; Wang, X.; Negro, A.; McLean, P.J.; Hyman, B.T.; Feany, M.B. Tyrosine and serine
phosphorylation of α-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.
J. Clin. Invest. 2009, 119, 3257–3265. [CrossRef]
189. Chen, L.; Feany, M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a
Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8, 657–663. [CrossRef]
190. Kuwahara, T.; Tonegawa, R.; Ito, G.; Mitani, S.; Iwatsubo, T. Phosphorylation of α-synuclein protein at
Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans.
J. Biol. Chem. 2012, 287, 7098–7109. [CrossRef]
191. Paleologou, K.E.; Schmid, A.W.; Rospigliosi, C.C.; Kim, H.-Y.; Lamberto, G.R.; Fredenburg, R.A.;
Lansbury, P.T.J.; Fernandez, C.O.; Eliezer, D.; Zweckstetter, M.; et al. Phosphorylation at Ser-129 but
not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 2008, 283,
16895–16905. [CrossRef] [PubMed]
192. Gorbatyuk, O.S.; Li, S.; Sullivan, L.F.; Chen, W.; Kondrikova, G.; Manfredsson, F.P.; Mandel, R.J.; Muzyczka, N.
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model
of Parkinson disease. Proc. Natl. Acad. Sci. USA 2008, 105, 763–768. [CrossRef] [PubMed]
193. Meier, F.; Abeywardana, T.; Dhall, A.; Marotta, N.P.; Varkey, J.; Langen, R.; Chatterjee, C.; Pratt, M.R.
Semisynthetic, site-specific ubiquitin modification of α-synuclein reveals differential effects on aggregation.
J. Am. Chem. Soc. 2012, 134, 5468–5471. [CrossRef] [PubMed]
194. Guerrero-Ferreira, R.; Kovacik, L.; Ni, D.; Stahlberg, H. New insights on the structure of alpha-synuclein
fibrils using cryo-electron microscopy. Curr. Opin. Neurobiol. 2020, 61, 89–95. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 8043 27 of 27
195. Souza, J.M.; Giasson, B.I.; Chen, Q.; Lee, V.M.; Ischiropoulos, H. Dityrosine cross-linking promotes formation
of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of
neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275, 18344–18349. [CrossRef] [PubMed]
196. Strohäker, T.; Jung, B.C.; Liou, S.H.; Fernandez, C.O.; Riedel, D.; Becker, S.; Halliday, G.M.; Bennati, M.;
Kim, W.S.; Lee, S.J.; et al. Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts.
Nat. Commun. 2019, 10, 1–12. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
